Not Signed In -
Dementia - Multi-Infarct |
|
|
Clinical Trial: Treatment of Elderly Subjects with Psychosis and Behavioral Disturbances Associated with Dementia of the Alzheimer''s Type
This study is not yet open for patient recruitment.
Verified by Solvay Pharmaceuticals August 2005
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| psychosis and behavioral disturbances associated with dementia of the alzheimer''''s type | Drug: bifeprunox | Phase III |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Tolerability Study of Bifeprunox in the Treatment of Elderly Subjects with Psychosis and Behavioral Disturbances Associated with Dementia of the Alzheimer''''s Type
Eligibility
Inclusion Criteria:
diagnosis of dementia of the alzheimer''''s type
Exclusion Criteria:
history of seizure disorder, clinically significant ECG, clinical or radiological evidence of stroke, vascular dementia or dementia due to substance abuse, head trauma
Location and Contact Information
Global Clinical Director Solvay, Study Director, Solvay Pharmaceuticals
More Information
Last Updated: September 11, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00160147
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
email this page
print this page
bookmark this page
feedback on this page
